Cancer Gene Therapy with Non-Viral Nanocarriers, 2nd Edition
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".
Deadline for manuscript submissions: 31 March 2025 | Viewed by 1597
Special Issue Editors
Interests: nanotechnology; liposomes; nanoemulsion; model lipid membranes; drug targeting
Special Issues, Collections and Topics in MDPI journals
Interests: molecular pharmacology/biology; gene therapy; clinical pharmacology; toxicology; determination of molecular mechanisms of cardiovascular and metabolic diseases
Special Issues, Collections and Topics in MDPI journals
Interests: pharmaceutical technology; nanotechnology; gene delivery; liposomes, nanocarrier development and characterization
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer is currently affecting millions of people worldwide and is considered to be one of the leading causes of death in the world. Conventional therapies for cancer treatment include surgery, radiotherapy and chemotherapy, but these interventions often cause severe side effects within patients due to their lack of specificity. As a result, new therapeutic treatments are needed which have an improved efficacy and reduced toxicity. One of these potential treatments is gene therapy, which aims to deliver genetic material to cancer cells in order to reduce or eliminate a tumor or repair errors that cause cells to become cancerous in an attempt to reverse their state. Various gene therapy approaches are used for cancer treatment, including the replacement/correction of missing or defective genes to suppress tumor formation, the modulation of the immune system to recognize cancer cells, silencing of oncogenes to suppress the formation or spreading of cancer, the use of suicide genes that cause the self-destruction of cancer cells, the use of antiogenetic genes to prevent tumor blood vessels from forming and the use of genes that increase the sensitivity of cancer cells to conventional therapies or protect healthy cells from them. The successful implementation of gene therapy requires carriers that can protect the genetic material and efficiently deliver it (alone or in combination with conventional therapeutics) specifically to cancer cells. Various delivery systems have been developed and studied, including viral vectors and non-viral systems, such as lipoplexes, polyplexes and inorganic nanoparticles. Non-viral vectors present various advantages such as their safety, low cost and ability to carry larger genetic materials, and they can be designed with specific properties.
For this Special Issue of Pharmaceutics, we invite researchers to submit original research articles focused on novel gene delivery strategies for cancer treatment using non-viral nanocarriers; these may include new genes or gene/conventional therapeutics combinations delivered with non-viral nanocarriers or new non-viral nanocarriers. Review articles on the latest advancements made in the above-mentioned areas are also welcome.
Dr. Sophia Hatziantoniou
Dr. Eleftheria Galatou
Dr. Elena Mourelatou
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanocarriers
- gene delivery
- lipoplexes
- polyplexes
- non-viral vectors
- cancer therapy
- transfection
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
Related Special Issue
- Cancer Gene Therapy With Non-Viral Nanocarriers in Pharmaceutics (7 articles)
